摘要
目的观察应用重组人促红细胞生成素(rHuEPO)纠正慢性肾功能不全(CRI)患者贫血对逆转左心室肥大(LVH)的影响。方法选择宁夏医学院附属医院肾脏内科51例未经肾脏替代治疗的患者随机分为两组：治疗组(T组)26例予以rHuEPO皮下注射治疗,起始量每周80～120u/Kg,血红蛋白(Hb)105～115g/L、红细胞压积(Hct)30%～35%时rHuEPO减为维持量；对照组(C组)25例不用rHuEPO治疗；两组在治疗过程中均积极控制血压在正常或接近正常水平。观察并比较两组患者Hb、Hct、左心室重量指数(LVMI)、血压收缩压(SBP)、舒张压(DBP)、内生肌酐清除率(ccr)情况。结果治疗前后两组在SBP、DBP、Ccr方面无显著差异,治疗后Hb、Hct T组较C组明显升高(P＜0．01),LVMI T组较治疗前及C组治疗前后明显降低(P＜0．01),两组血压水平无明显变化(P＞0．05)。结论纠正CRI患者的贫血可部分逆转其LVH。
Objective To investigate the efficacy of recombinant human erythropoietin （rHuEP0） on reverse left ventricular hypertrophy （LVH） by improving anemia in chronic renal insufficiency （CRI） patients. Methods Fifty-one patients who were diagnosed as CRI withont receiving renal replacement therapy were randomly divided into two groups, Treatment group （group T） and control group （group C）. In group T the 26 patients were given rHuEP0 100-I20U/ Kg/wk through hypodermic injection at beginning, when the hemoglobin （Hb） reached 105-115g/ L and the hematocrit （Hct） was 30%-50%, the dose of rHuEP0 should decreased to maintenance dose, In （group C） the 25 patients didn＇t receive rHuEP0 therapy the blood pressure of all patients in the two groups were at the normal or near normal level during the treatment. The two groups＇ Hb, Hct, left ventricular mass index（LVMI）, systolic blood pressure（SBP）, diastolic blood pressure（DBP） and endogenous creatinine clearance（Ccr） were compared. Results ① There were no significant change in SBP,DBP and Ccr between the two groups after the treatment. ②Hb and Hct increased significantly in group T after treatment（P〈0.01）. ③LVMI in group T after treatment were lower than that before treatment and in group C（P〈0.01）.④There were no significant difference of the blood pressure in two groups（P〉0.05）. Condusion rHuEP0 therapy can reverse LVH through rectify the anemia of CRI patients.
出处
《中国血液净化》
2006年第10期717-719,共3页
Chinese Journal of Blood Purification
关键词
慢性肾功能不全
贫血
左心室肥大
Chronic renal insufficiency
Anemia
Left ventricular hypertrophy
